Flurotor 500 mg (Fluorouracil) Injection – Comprehensive Cancer Therapy
Overview:
Flurotor 500 mg Injection, containing the potent anticancer agent Fluorouracil, is a widely used chemotherapy drug manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma. This injectable treatment plays a pivotal role in managing multiple solid tumors, including those of the colon, breast, liver, pancreas, bladder, cervix, lung, stomach, and ovaries.
Flurotor is particularly effective in targeting rapidly dividing cancer cells, making it a vital component in both monotherapy and combination chemotherapy protocols. It is available in a convenient injectable form, ensuring quick and efficient delivery of treatment in clinical oncology settings.
Key Indications of Flurotor 500 mg Injection:
Flurotor is indicated alone or in combination therapy for the treatment of:
Colon or rectal carcinoma
Stomach and pancreatic cancers
Liver cancer
Breast cancer
Bladder carcinoma
Lung carcinoma
Epithelial ovarian cancer
Cervical cancer
Pharmacological Action:
Fluorouracil, the active ingredient in Flurotor, is a pyrimidine analog that becomes active within the body after conversion into 5-fluorodeoxyuridine monophosphate (FdUMP). This active metabolite inhibits thymidylate synthase, an essential enzyme for DNA synthesis, thus disrupting cancer cell replication.
FdUMP also integrates into RNA, causing faulty RNA function, and primarily affects proliferating cells in the G2 and S phases of the cell cycle. Its dual action on DNA and RNA synthesis makes it highly effective in halting tumor progression.
Dosage and Administration:
Flurotor is administered intravenously either by rapid bolus injection or slow infusion. It may also be delivered via intra-arterial infusion in specific cases.
Common Dosage Regimens Include:
Standard IV Dosage: 12–13.5 mg/kg (500 mg/m²) daily for 5 days, repeated every 4 weeks.
Slow Infusion: 5-day infusion of diluted Fluorouracil in 500 ml 5% dextrose over 2–3 hours.
Palliative Cancer Management: Begins with 12 mg/kg/day for 4 days, with adjustments based on patient response.
Low-Risk Patients: Reduced dosing of 6 mg/kg/day for 3 days.
Maintenance Therapy: 10–15 mg/kg/week or repeated monthly based on previous toxicity.
Special Notes:
Combination with radiation: 5–10 mg/kg/day.
Combination with other anticancer drugs: Commonly used with methotrexate and cyclophosphamide.
Use in children: Based on adult dosing; however, pediatric safety is not fully established.
Drug Interactions:
Cimetidine: Increases plasma levels of Fluorouracil due to hepatic enzyme inhibition.
Other cytotoxic agents or radiation therapy: May increase hematologic toxicity.
Contraindications:
Severe bone marrow suppression
Pregnancy and lactation
Non-malignant conditions
Patients with severe debilitation due to other treatments
Side Effects of Flurotor Injection:
Severe Effects:
Myelosuppression (leukopenia, thrombocytopenia)
Cardiotoxicity (ischemic events, arrhythmias)
Neurotoxicity (ataxia, cerebellar syndromes)
Severe gastrointestinal reactions: Diarrhea, stomatitis, nausea, and vomiting
Moderate to Mild Effects:
Hand-foot syndrome
Rash or allergic reactions
Hair loss (temporary)
Conjunctivitis
Confusion and balance problems
Toxicity monitoring is essential as therapeutic success is often linked to the appearance of controlled side effects.
Precautions & Warnings:
Regular blood count monitoring is vital.
Treatment must be immediately stopped in case of leukopenia, thrombocytopenia, or severe GI toxicity.
Only experienced oncology professionals should administer this drug.
Pregnancy & Lactation Warning:
Absolutely contraindicated during pregnancy (especially in the first trimester).
Breastfeeding is not recommended due to potential harm to the infant.
Use in Special Populations:
Neonates & Children: Use with caution; safety not established.
Elderly: Dose adjustment based on weight and general condition.
Overdose Management:
No specific antidote exists.
Supportive treatment is key.
Common signs include extreme fatigue, myelosuppression, mucositis, and bleeding.
Reconstitution & Handling:
Flurotor is a cytotoxic drug. Use protective gear and designated preparation areas when reconstituting. Avoid exposure to skin or mucous membranes. Dispose of waste properly as per hazardous material guidelines.
Storage Conditions:
Store in original packaging below 25°C.
Do not refrigerate or freeze.
Protect from direct sunlight.
Manufacturer Information:
Eskayef Pharmaceuticals Ltd. – A globally recognized pharmaceutical manufacturer from Bangladesh, offering premium-quality medications since 1990. Eskayef’s focus on global health is reflected in its wide portfolio of oncology medicines and its adherence to international quality standards.
🔗 Visit: www.skfbd.com
Supplied By: Saif Pharma
Saif Pharma is a professional oncology medicine supplier operating across 60+ countries, including the USA, Canada, UAE, and Pakistan. Since 2014, Saif Pharma has committed itself to delivering affordable and reliable cancer treatment options globally.
🔗 Visit: www.saifpharma.com
